119 related articles for article (PubMed ID: 38734644)
21. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease.
García-Bernal D; Palomo M; Martínez CM; Millán-Rivero JE; García-Guillén AI; Blanquer M; Díaz-Ricart M; Sackstein R; Carreras E; Moraleda JM
J Cell Mol Med; 2020 Jul; 24(14):8031-8044. PubMed ID: 32519822
[TBL] [Abstract][Full Text] [Related]
22. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
23. Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.
Tilmont R; Yakoub-Agha I; Ramdane N; Srour M; Coiteux V; Magro L; Odou P; Simon N; Beauvais D
Ann Pharmacother; 2022 Sep; 56(9):1007-1015. PubMed ID: 35016532
[TBL] [Abstract][Full Text] [Related]
24. Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK; Ostrowski SR; Jørgensen NR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transpl Immunol; 2022 Oct; 74():101650. PubMed ID: 35718288
[TBL] [Abstract][Full Text] [Related]
25. Pretransplant β2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant.
Costa-Lima C; Miranda ECM; Colella MP; Aranha FJP; de Souza CA; Vigorito AC; De Paula EV
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1329-1332. PubMed ID: 27044906
[TBL] [Abstract][Full Text] [Related]
26. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
27. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
28. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
29. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
[TBL] [Abstract][Full Text] [Related]
30. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease.
Yin J; Wang C; Huang M; Mao X; Zhou J; Zhang Y
Cancer Med; 2016 Jul; 5(7):1654-69. PubMed ID: 27109254
[TBL] [Abstract][Full Text] [Related]
31. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
33. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
34. Association between CD34
Yao D; Li B; Chu X; Pan J; Meng L; Hu Y; Gao L; Li J; Tian Y; Hu S
Transpl Immunol; 2023 Apr; 77():101779. PubMed ID: 36596428
[TBL] [Abstract][Full Text] [Related]
35. Machine Learning Classification Algorithms to Predict aGvHD following Allo-HSCT: A Systematic Review.
Salehnasab C; Hajifathali A; Asadi F; Roshandel E; Kazemi A; Roshanpoor A
Methods Inf Med; 2019 Dec; 58(6):205-212. PubMed ID: 32349154
[TBL] [Abstract][Full Text] [Related]
36. A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation.
Han L; Zhao K; Li Y; Han H; Zhou L; Ma P; Fan Z; Sun H; Jin H; Jiang Z; Liu Q; Peng J
Am J Transplant; 2020 Apr; 20(4):1014-1027. PubMed ID: 31605563
[TBL] [Abstract][Full Text] [Related]
37. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
Guru Murthy GS; Logan BR; Bo-Subait S; Beitinjaneh A; Devine S; Farhadfar N; Gowda L; Hashmi S; Lazarus H; Nathan S; Sharma A; Yared JA; Stefanski HE; Pulsipher MA; Hsu JW; Switzer GE; Panch SR; Shaw BE
Am J Hematol; 2023 Apr; 98(4):608-619. PubMed ID: 36606713
[TBL] [Abstract][Full Text] [Related]
38. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
39. Pre-transplant donor CD4
Rubio MT; Bouillié M; Bouazza N; Coman T; Trebeden-Nègre H; Gomez A; Suarez F; Sibon D; Brignier A; Paubelle E; Nguyen-Khoc S; Cavazzana M; Lantz O; Mohty M; Urien S; Hermine O
Leukemia; 2017 Apr; 31(4):903-912. PubMed ID: 27740636
[TBL] [Abstract][Full Text] [Related]
40. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation.
Gimondi S; Dugo M; Vendramin A; Bermema A; Biancon G; Cavané A; Corradini P; Carniti C
Exp Hematol; 2016 Jul; 44(7):624-634.e1. PubMed ID: 27013207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
